
”Some of the best news ALK has had in years,” ALK CEO Carsten Hellman tells MarketWire.
Hellmann is referring to the news that the Chinese health authorities have opened the door for ALK to file house dust mite (HDM) treatment Acarizax for registration in China, despite being yet to finish a clinical trial with Chinese patients.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app